The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global radiopharmaceuticals market was valued at US$ 4.9 Billion in 2021.
We expect the global radiopharmaceuticals market to exhibit a CAGR of 6.76% during 2022-2027.
The sudden outbreak of the COVID-19 pandemic had led to the postponement of numerous elective treatments for reducing the risk of the coronavirus infection upon hospital visits, thereby negatively impacting the global market for radiopharmaceuticals.
The rising prevalence of acute and chronic diseases, along with the growing adoption of radiopharmaceuticals by physicians during diagnosis, is primarily driving the global radiopharmaceuticals market.
Based on the product type, the global radiopharmaceuticals market can be categorized into diagnostic nuclear medicine and therapeutic nuclear medicine. Currently, diagnostic nuclear medicine accounts for the majority of the total market share.
Based on the application, the global radiopharmaceuticals market has been segregated into oncology, cardiology, neurology, endocrinology, and others. Among these, oncology currently holds the largest market share.
Based on the end use, the global radiopharmaceuticals market can be bifurcated into hospitals and clinics, research institutes, and diagnostic centers. Currently, diagnostic centers exhibit a clear dominance in the market.
On a regional level, the market has been classified into North America, Asia-Pacific, Europe, Latin America, and Middle East and Africa, where North America currently dominates the global market.
Some of the major players in the global radiopharmaceuticals market include Advanced Accelerator Applications (Novartis AG), Bayer AG, Bracco S.p.A., Cardinal Health Inc., Curium Pharma, General Electric Company, IBA RadioPharma Solutions, Jubilant Pharma Limited, Lantheus Medical Imaging Inc, Nordion Inc. (Sotera Health), NTP Radioisotopes SOC Ltd, PharmaLogic Holdings Corp., and Siemens AG.
Home Healthcare Market by Product (Therapeutic Products, Testing, Screening, and Monitoring Products, Mobility Care Products), Service (Skilled Nursing, Rehabilitation Therapy, Hospice & Palliative Care, Unskilled Care, Respiratory Therapy, Infusion Therapy, Pregnancy Care), Indication (Cancer, Respiratory Diseases, Movement Disorders, Cardiovascular Diseases & Hypertension, Pregnancy, Wound Care, Diabetes, Hearing Disorders, and Others), and Region 2023-2028
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at